In 2022, Modvig et al were the first to demonstrate an association between a CD34+CD38dim+nTdTdim+ immunophenotype on leukemic blasts in Philadelphia (Ph)-negative BCP-ALL and poor therapy response, predicting a PCR-MRD≥10−5 at the end of induction (EOI) on day 29. This evidence concerns the gene CD34 and acute lymphoblastic leukemia.